Poly(ethyleneglycol) 500 Dimethylether as Novel Solvent for Injectable In Situ Forming Depots

@article{Schoenhammer2009Polyethyleneglycol5D,
  title={Poly(ethyleneglycol) 500 Dimethylether as Novel Solvent for Injectable In Situ Forming Depots},
  author={Karin Schoenhammer and Holger Petersen and Frank Guethlein and Achim M. Goepferich},
  journal={Pharmaceutical Research},
  year={2009},
  volume={26},
  pages={2568-2577}
}
PurposePoly(D,L-lactide-co-glycolide) (PLGA) solutions in poly(ethyleneglycol)600 (PEG600), N-methyl-2-pyrrolidone (NMP) and poly(ethyleneglycol)500dimethylether (PEG500DME) as a novel solvent, were investigated as suitable for use in injectable in situ forming depots (ISFD).MethodsThe hemolytic potential of the solvents was investigated. Viscosimetry was used to determine rheological properties of solvents and PLGA solutions. DSC was used to evaluate the stability of the PLGA solutions through… 
Biocompatibility of an injectable in situ forming depot for peptide delivery.
TLDR
The functionality of the ISFD containing PEG 500DME as a novel solvent was demonstrated in vitro and in vivo and the local tolerability of the system confirmed the biocompatibility of PEG500DME in parenteral depots.
In situ forming parenteral depot systems based on poly(ethylene carbonate): effect of polymer molecular weight on model protein release.
Chitosan/glucose 1-phosphate as new stable in situ forming depot system for controlled drug delivery.
  • Stéphanie Supper, N. Anton, T. Vandamme
  • Materials Science
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2014
Initial Leuprolide Acetate Release from Poly(d,l-lactide-co-glycolide) in Situ Forming Implants as Studied by Ultraviolet-Visible Imaging.
TLDR
The findings show that the external environment affects the solvent exchange kinetics for in situ forming implants in vitro, resulting in different types of initial release behavior.
Release of human growth hormone from an in-situ implant modulated by poly(ethylene glycol) dimethyl ether and tris(hydroxymethyl) aminomethane
TLDR
Results of the ISIs containing PEG-DME and Tris injection in rabbits demonstrated a reduced tissue inflammation and the 14-days serum levels of the hGH and IGF-1 of this system in recipient rabbits were comparable to those of the commercial daily injection samples.
A novel risperidone-loaded SAIB–PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo
TLDR
It is demonstrated that the SAIB–PLGA mixture matrix depot could be useful as a sustained delivery system for risperidone.
Self-assembled drug delivery system based on low-molecular-weight bis-amide organogelator: synthesis, properties and in vivo evaluation
TLDR
The in situ forming l-lysine-derivative-based organogel could be a promising matrix for sustained drug delivery of the drugs with low solubility.
Investigation of Fragment Antibody Stability and Its Release Mechanism from Poly(Lactide-co-Glycolide)-Triacetin Depots for Sustained-Release Applications.
TLDR
The unprecedented release profile and retention of greater than 80% of antigen-binding capacity even after several weeks demonstrates that PLGA-triacetin solution could be a promising system for the long-term delivery of biologics.
...
...

References

SHOWING 1-10 OF 22 REFERENCES
Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
Drug release from injectable depots: two different in vitro mechanisms.
Effects of ethyl benzoate on performance, morphology, and erosion of PLGA implants formed in situ
TLDR
The effect of EB on performance, erosion, and morphology is explained by means of solvent–nonsolvent affinity, water permeation, and the rate of phase inversion.
Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior.
TLDR
Results showed that the amount of drug released over the first 24 h (36% +/- 0.34%) (burst release), for formulation prepared with polymer RG 503H (medium molecular weight, M(w) 34 kDa), was significantly higher than others (p < 0.05).
Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.
Thermal characterization of polyethylene glycols applied in the pharmaceutical technology using differential scanning calorimetry and hot stage microscopy
In the present study, the effect of the molecular weight and thermal treatments on commercial polyethylene glycols (PEG) samples used in the pharmaceutical processing technology, has been analyzed
Sustained Release of Human Growth Hormone from PLGA Solution Depots
TLDR
The hypothesis that, in a slow phase-inverting system, drug release over the first few weeks is governed by the diffusion rate of drug through the polymer solution is supported.
...
...